双鹭药业
(002038)
| 流通市值：67.22亿 | | | 总市值：81.06亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 383,945,973.08 | 346,304,398.88 | 328,747,917.07 | 411,958,243.66 |
| 交易性金融资产 | 569,625,262.62 | 540,639,787.88 | 456,087,288.99 | 480,855,467.52 |
| 应收票据及应收账款 | 90,392,068.08 | 85,985,897.64 | 100,483,666.91 | 102,965,551.13 |
| 应收账款 | 90,392,068.08 | 85,985,897.64 | 100,483,666.91 | 102,965,551.13 |
| 应收款项融资 | 263,340 | - | - | 2,822,933.53 |
| 预付款项 | 117,179,710.95 | 116,292,983.1 | 153,479,508.72 | 121,155,659.03 |
| 其他应收款合计 | 14,907,460.95 | 15,137,646.67 | 15,223,716.54 | 15,647,268.06 |
| 存货 | 394,807,069.61 | 415,420,300.1 | 403,254,298.06 | 246,333,789.57 |
| 一年内到期的非流动资产 | 231,950,750.02 | 260,864,500 | 328,251,388.9 | 325,713,888.89 |
| 其他流动资产 | 783,328,708.08 | 782,097,512.2 | 776,260,991.85 | 781,386,164.26 |
| 流动资产合计 | 2,586,400,343.39 | 2,562,743,026.47 | 2,561,788,777.04 | 2,488,838,965.65 |
| 非流动资产: | | | | |
| 长期股权投资 | 953,590,419.26 | 956,086,892.46 | 954,827,731.35 | 951,933,309.68 |
| 其他非流动金融资产 | 268,435,965.54 | 279,813,440.57 | 279,837,831.19 | 279,545,423.72 |
| 投资性房地产 | 12,497,110.89 | 12,723,542.64 | 12,949,974.39 | 13,176,406.14 |
| 固定资产 | 402,296,608.19 | 404,786,780.85 | 413,163,165.64 | 419,321,790.24 |
| 在建工程 | 130,931,342.4 | 122,149,772.99 | 99,844,535.09 | 94,922,038.39 |
| 无形资产 | 683,977,749.37 | 695,530,411.68 | 713,137,683.23 | 678,581,445.8 |
| 开发支出 | 488,269,613.29 | 486,076,956.2 | 479,761,974.97 | 517,283,516.42 |
| 长期待摊费用 | 1,579,230.82 | 1,579,230.82 | 1,718,700.9 | 1,718,700.9 |
| 递延所得税资产 | 64,077,990.71 | 64,373,928.84 | 65,836,193.3 | 69,522,944.42 |
| 其他非流动资产 | 436,631,764.47 | 432,017,039.32 | 481,836,271.96 | 464,174,777.38 |
| 非流动资产合计 | 3,442,287,794.94 | 3,455,137,996.37 | 3,502,914,062.02 | 3,490,180,353.09 |
| 资产总计 | 6,028,688,138.33 | 6,017,881,022.84 | 6,064,702,839.06 | 5,979,019,318.74 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 55,345,005.74 | 49,045,557.32 | 139,278,548.4 | 122,285,265.92 |
| 其中：应付票据 | 18,694,879 | 8,474,343.7 | 10,538,577.6 | 1,260,000 |
| 应付账款 | 36,650,126.74 | 40,571,213.62 | 128,739,970.8 | 121,025,265.92 |
| 预收款项 | 937,661.3 | 847,744.5 | 110,822.8 | 25,830.7 |
| 合同负债 | 74,663,207.35 | 75,567,317.95 | 106,387,042.1 | 70,506,152.62 |
| 应付职工薪酬 | 36,568,265.63 | 35,488,979.94 | 37,100,791.91 | 42,948,812.36 |
| 应交税费 | 2,067,914.68 | 2,378,182.41 | 2,573,778.48 | 3,486,281.89 |
| 其他应付款合计 | 36,689,771.53 | 34,177,680.39 | 43,754,567.11 | 47,598,720.46 |
| 其他流动负债 | 2,766,829.06 | 2,806,867.85 | 4,789,340.12 | 2,554,056.36 |
| 流动负债合计 | 209,038,655.29 | 200,312,330.36 | 333,994,890.92 | 289,405,120.31 |
| 非流动负债: | | | | |
| 递延收益 | 41,166,185.23 | 41,166,185.23 | 41,166,185.23 | 43,996,123.1 |
| 递延所得税负债 | 77,751,457.74 | 75,131,398.81 | 63,276,340.2 | 64,969,835.95 |
| 非流动负债合计 | 118,917,642.97 | 116,297,584.04 | 104,442,525.43 | 108,965,959.05 |
| 负债合计 | 327,956,298.26 | 316,609,914.4 | 438,437,416.35 | 398,371,079.36 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 |
| 资本公积 | 49,615,655.87 | 49,615,655.87 | 49,615,655.87 | 49,615,655.87 |
| 其他综合收益 | 13,474,826.25 | 13,474,826.25 | 13,474,826.25 | 13,474,826.25 |
| 盈余公积 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 |
| 未分配利润 | 3,970,148,074.32 | 3,970,645,232.24 | 3,895,565,435.16 | 3,849,597,029.54 |
| 归属于母公司股东权益合计 | 5,692,998,987.18 | 5,693,496,145.1 | 5,618,416,348.02 | 5,572,447,942.4 |
| 少数股东权益 | 7,732,852.89 | 7,774,963.34 | 7,849,074.69 | 8,200,296.98 |
| 股东权益合计 | 5,700,731,840.07 | 5,701,271,108.44 | 5,626,265,422.71 | 5,580,648,239.38 |
| 负债和股东权益合计 | 6,028,688,138.33 | 6,017,881,022.84 | 6,064,702,839.06 | 5,979,019,318.74 |
| 公告日期 | 2025-10-27 | 2025-08-26 | 2025-04-22 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |